Personalized cancer vaccine shows promise in small kidney cancer trial

In a small clinical trial, nine patients with renal cell carcinoma—the most common form of kidney cancer in adults—have not experienced a recurrence of the disease after receiving a personalized cancer vaccine. Participants were monitored for an average of three years and four months following surgery.

The experimental vaccine works by analyzing an individual patient's tumor to identify unique protein fragments, known as neoantigens, which are then used to create a vaccine that trains the immune system to recognize and attack specific cancer cells. In the study, all nine patients developed an immune response, and seven successfully activated T-cells that recognized their own tumors.

Researchers David Braun of Yale University and Toni Choueiri of the Dana-Farber Cancer Institute cautioned that the results must be interpreted with care. Because the study involved a limited number of patients and lacked a control group, it cannot definitively prove the vaccine prevented recurrence or determine the impact of additional immunotherapy drugs used by some participants.